Literature DB >> 26627550

Immunopathogenesis of IBD: current state of the art.

Heitor S P de Souza1, Claudio Fiocchi2.   

Abstract

IBD is a chronic inflammatory condition of the gastrointestinal tract encompassing two main clinical entities: Crohn's disease and ulcerative colitis. Although Crohn's disease and ulcerative colitis have historically been studied together because they share common features (such as symptoms, structural damage and therapy), it is now clear that they represent two distinct pathophysiological entities. Both Crohn's disease and ulcerative colitis are associated with multiple pathogenic factors including environmental changes, an array of susceptibility gene variants, a qualitatively and quantitatively abnormal gut microbiota and a broadly dysregulated immune response. In spite of this realization and the identification of seemingly pertinent environmental, genetic, microbial and immune factors, a full understanding of IBD pathogenesis is still out of reach and, consequently, treatment is far from optimal. An important reason for this unsatisfactory situation is the currently limited comprehension of what are the truly relevant components of IBD immunopathogenesis. This article will comprehensively review current knowledge of the classic immune components and will expand the concept of IBD immunopathogenesis to include various cells, mediators and pathways that have not been traditionally associated with disease mechanisms, but that profoundly affect the overall intestinal inflammatory process.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26627550     DOI: 10.1038/nrgastro.2015.186

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  230 in total

Review 1.  Interplay between the TH17 and TReg cell lineages: a (co-)evolutionary perspective.

Authors:  Casey T Weaver; Robin D Hatton
Journal:  Nat Rev Immunol       Date:  2009-12       Impact factor: 53.106

2.  Low exposure to sunlight is a risk factor for Crohn's disease.

Authors:  V Nerich; P Jantchou; M-C Boutron-Ruault; E Monnet; A Weill; V Vanbockstael; G-R Auleley; C Balaire; P Dubost; S Rican; H Allemand; F Carbonnel
Journal:  Aliment Pharmacol Ther       Date:  2011-02-20       Impact factor: 8.171

Review 3.  Integrative inflammasome activity in the regulation of intestinal mucosal immune responses.

Authors:  E Elinav; J Henao-Mejia; R A Flavell
Journal:  Mucosal Immunol       Date:  2012-12-05       Impact factor: 7.313

4.  Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection.

Authors:  Maria Van der Sluis; Barbara A E De Koning; Adrianus C J M De Bruijn; Anna Velcich; Jules P P Meijerink; Johannes B Van Goudoever; Hans A Büller; Jan Dekker; Isabelle Van Seuningen; Ingrid B Renes; Alexandra W C Einerhand
Journal:  Gastroenterology       Date:  2006-07       Impact factor: 22.682

5.  Pro-angiogenic activity of TLRs and NLRs: a novel link between gut microbiota and intestinal angiogenesis.

Authors:  Anja Schirbel; Sean Kessler; Florian Rieder; Gail West; Nancy Rebert; Kewal Asosingh; Christine McDonald; Claudio Fiocchi
Journal:  Gastroenterology       Date:  2012-11-10       Impact factor: 22.682

6.  p53 negatively regulates intestinal immunity by delaying mucosal T cell cycling.

Authors:  Andreas Sturm; Jugoh Itoh; James W Jacobberger; Claudio Fiocchi
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

Review 7.  The role of bacteria and pattern-recognition receptors in Crohn's disease.

Authors:  Si Ming Man; Nadeem O Kaakoush; Hazel M Mitchell
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-02-08       Impact factor: 46.802

8.  Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease.

Authors:  S Schreiber; T Heinig; H G Thiele; A Raedler
Journal:  Gastroenterology       Date:  1995-05       Impact factor: 22.682

Review 9.  Role of neuropeptides in inflammatory bowel disease.

Authors:  Kara J Gross; Charalabos Pothoulakis
Journal:  Inflamm Bowel Dis       Date:  2007-07       Impact factor: 5.325

Review 10.  The unusual suspects--innate lymphoid cells as novel therapeutic targets in IBD.

Authors:  Rimma Goldberg; Natalie Prescott; Graham M Lord; Thomas T MacDonald; Nick Powell
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-05       Impact factor: 46.802

View more
  389 in total

1.  IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease.

Authors:  Lyssia Belarif; Richard Danger; Laetitia Kermarrec; Véronique Nerrière-Daguin; Sabrina Pengam; Tony Durand; Caroline Mary; Elise Kerdreux; Vanessa Gauttier; Aneta Kucik; Virginie Thepenier; Jerome C Martin; Christie Chang; Adeeb Rahman; Nina Salabert-Le Guen; Cécile Braudeau; Ahmed Abidi; Grégoire David; Florent Malard; Celine Takoudju; Bernard Martinet; Nathalie Gérard; Isabelle Neveu; Michel Neunlist; Emmanuel Coron; Thomas T MacDonald; Pierre Desreumaux; Hoa-Le Mai; Stephanie Le Bas-Bernardet; Jean-François Mosnier; Miriam Merad; Régis Josien; Sophie Brouard; Jean-Paul Soulillou; Gilles Blancho; Arnaud Bourreille; Philippe Naveilhan; Bernard Vanhove; Nicolas Poirier
Journal:  J Clin Invest       Date:  2019-04-02       Impact factor: 14.808

2.  Platelet hyaluronidase-2 regulates the early stages of inflammatory disease in colitis.

Authors:  Aaron C Petrey; Dana R Obery; Sean P Kessler; Ash Zawerton; Bruno Flamion; Carol A de la Motte
Journal:  Blood       Date:  2019-07-01       Impact factor: 22.113

Review 3.  Probiotics, Prebiotics, and Synbiotics for the Prevention of Necrotizing Enterocolitis.

Authors:  Kathene C Johnson-Henry; Thomas R Abrahamsson; Richard You Wu; Philip M Sherman
Journal:  Adv Nutr       Date:  2016-09-15       Impact factor: 8.701

4.  Effect of chemical modulation of toll-like receptor 4 in an animal model of ulcerative colitis.

Authors:  Fabio Alessandro Facchini; Davide Di Fusco; Simona Barresi; Andrea Luraghi; Alberto Minotti; Francesca Granucci; Giovanni Monteleone; Francesco Peri; Ivan Monteleone
Journal:  Eur J Clin Pharmacol       Date:  2020-01-25       Impact factor: 2.953

Review 5.  Resolution of Crohn's disease.

Authors:  Heike Schmitt; Clemens Neufert; Markus F Neurath; Raja Atreya
Journal:  Semin Immunopathol       Date:  2019-09-24       Impact factor: 9.623

6.  PPARγ-activation increases intestinal M1 macrophages and mitigates formation of serrated adenomas in mutant KRAS mice.

Authors:  Tobias Gutting; Christian A Weber; Philip Weidner; Frank Herweck; Sarah Henn; Teresa Friedrich; Shuiping Yin; Julia Kzhyshkowska; Timo Gaiser; Klaus-Peter Janssen; Wolfgang Reindl; Matthias P A Ebert; Elke Burgermeister
Journal:  Oncoimmunology       Date:  2018-02-01       Impact factor: 8.110

7.  Relapse Prevention by Plant-Based Diet Incorporated into Induction Therapy for Ulcerative Colitis: A Single-Group Trial.

Authors:  Mitsuro Chiba; Kunio Nakane; Tsuyotoshi Tsuji; Satoko Tsuda; Hajime Ishii; Hideo Ohno; Kenta Watanabe; Yu Obara; Masafumi Komatsu; Takeshi Sugawara
Journal:  Perm J       Date:  2019

Review 8.  The Role of the Intestinal Microbiome in Type 1 Diabetes Pathogenesis.

Authors:  James C Needell; Danny Zipris
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

Review 9.  Crohn's disease.

Authors:  Giulia Roda; Siew Chien Ng; Paulo Gustavo Kotze; Marjorie Argollo; Remo Panaccione; Antonino Spinelli; Arthur Kaser; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Nat Rev Dis Primers       Date:  2020-04-02       Impact factor: 52.329

Review 10.  Recent Advances in the Etiopathogenesis of Inflammatory Bowel Disease: The Role of Omics.

Authors:  Eleni Stylianou
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.